

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 November 2022 (24.11.2022)



(10) International Publication Number
WO 2022/245759 A2

- (51) **International Patent Classification:**
A61K 47/68 (2017.01) *C07K 16/28* (2006.01)
- (21) **International Application Number:**
PCT/US2022/029535
- (22) **International Filing Date:**
17 May 2022 (17.05.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/189,522 17 May 2021 (17.05.2021) US
- (71) **Applicant:** **BIOHAVEN THERAPEUTICS LTD.**
[US/US]; 215 Church Street, New Haven, Connecticut
06510 (US).
- (72) **Inventors:** **KAZMIERSKI, Wieslaw**; Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US). **DUBOWCHIK, Gene M.**; Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US). **CALDWELL, Reese M.**; Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US). **SPIEGEL, David Adam**; Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US).
- (74) **Agent:** **ZUEV, Dmitry**; Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*

(54) **Title:** AGENTS FOR DIRECTED CONJUGATION TECHNIQUES AND CONJUGATED PRODUCTS

FIG. 4B



(57) **Abstract:** Among other things, the present disclosure provides technologies for site-directed conjugation of various moieties of interest to target agents. In some embodiments, the present disclosure utilizes target binding moieties to provide high conjugation efficiency and selectivity. In some embodiments, provided technologies are useful for preparing antibody conjugates.

WO 2022/245759 A2